Pure Global AI
NCT06358313Recruiting

Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Minor Stroke or TIA

Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Minor Stroke or TIA, a Randomized Controlled Single-blinded Trial
Kafrelsheikh UniversityPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ischemic Stroke
Drug/Device/Intervention
Atorvastatin 40mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Kafrelsheikh University
Location
Kafr Ash Shaykh, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Apr 10, 2024
End date
May 10, 2025
Enrollment
600 participants
Primary outcome

the rate of new stroke at 90 days

Summary

Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in
 the first 24 hours on the clinical outcomes of first-ever minor stroke or TIA patients
 treated with clopidogrel and aspirin assessed through NIHSS, mRS, and possible adverse
 effects.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedOther cerebral infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06358313
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06358313 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.